B. 1. Monnereau, A. Remontet, L. Maynadié, and M. , Estimation nationale de l'incidence des cancers en France entre 1980 et 2012

N. Howlader, A. Noone, and M. Krachpo, Cancer Statistics Review, 1975-2013 -SEER Statistics. https://seer.cancer.gov/csr, 2016.

A. Katz, V. Chia, W. Schoonen, and M. Kelsh, Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden, Cancer Causes & Control, vol.98, issue.11, pp.1627-1642, 2015.
DOI : 10.1007/s12185-013-1364-2

G. Murthy, G. Venkitachalam, R. Mehta, and P. , Trends in survival outcomes of B-lineage acute lymphoblastic leukemia in elderly patients: analysis of Surveillance, Epidemiology, and End Results database, Leukemia & Lymphoma, vol.92, issue.8, pp.2296-2300, 2015.
DOI : 10.1182/blood-2012-07-379016

J. Bennett, D. Catovsky, and M. Daniel, Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group, British Journal of Haematology, vol.1, issue.4, pp.451-458, 1976.
DOI : 10.1111/j.1365-2141.1976.tb03563.x

M. Bene, G. Castoldi, and W. Knapp, Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL), Leukemia, issue.10, pp.1783-1789, 1995.

D. E. Hossfeld, N. L. Jaffe, H. Harris, and . Stein, E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Annals of Oncology, vol.13, issue.3, pp.490-491, 2002.
DOI : 10.1093/annonc/mdf146

J. Vardiman, J. Thiele, and D. Arber, The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes, Blood, vol.114, issue.5, pp.937-951, 2009.
DOI : 10.1182/blood-2009-03-209262

D. Arber, A. Orazi, and R. Hasserjian, The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood, vol.127, issue.20, pp.2391-2405, 2016.
DOI : 10.1182/blood-2016-03-643544

L. Secker-walker, S. Lawler, R. Hardisty, L. Secker-walker, J. Chessells et al., Prognostic implications of chromosomal findings in acute lymphoblastic leukaemia at diagnosis Chromosomes and other prognostic factors in acute lymphoblastic leukaemia: a long-term follow-up Chromosomal abnormalities and their clinical significance in acute lymphoblastic leukemia, Third International Workshop on Chromosomes in Leukemia, pp.1529-1530336, 1978.

S. Propp, L. F. Brief-report, J. Priest, L. Robison, and R. Mckenna, Philadelphia chromosome positive childhood acute lymphoblastic leukemia Cytogenetic Abnormalities in Adult Acute Lymphoblastic Leukemia-Correlations with Hematologic Findings and Outcome. A Collaborative Study of the Groupe Français de Cytogénétique Hématologique .pdf. Blood;1996. 16 Cytogenetics in the management of children and adult acute lymphoblastic leukemia (ALL): an update by the Groupe francophone de cytogénétique hématologique (GFCH), Blood Ann Biol Clin (Paris), vol.5674, issue.15, pp.15-22, 1980.

J. Huret, M. Ahmad, and M. Arsaban, Atlas of Genetics and Cytogenetics in Oncology and Haematology in 2013, Nucleic Acids Research, vol.41, issue.D1, pp.920-924, 2013.
DOI : 10.1093/nar/gks1082

URL : https://hal.archives-ouvertes.fr/hal-01587507

D. Harper and P. Aplan, Chromosomal Rearrangements Leading to MLL Gene Fusions: Clinical and Biological Aspects, Cancer Research, vol.68, issue.24, pp.10024-10027, 2008.
DOI : 10.1158/0008-5472.CAN-08-2208

C. Meyer, J. Hofmann, and T. Burmeister, The MLL recombinome of acute leukemias in 2013, Leukemia, vol.23, issue.11, pp.2165-2176, 2013.
DOI : 10.1038/sj.onc.1207837

G. Issa, H. Kantarjian, and C. Yin, Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease, Cancer, vol.45, issue.3, pp.186-191, 1994.
DOI : 10.1038/ng.2532

M. Zhou, L. Gao, and Y. Jing, Detection of ETV6 gene rearrangements in adult acute lymphoblastic leukemia The impact of TEL-AML1 (ETV6-RUNX1) expression in precursor B cells and implications for leukaemia using three different genomewide screening methods, Ann Hematol Blood Cancer J, vol.913, issue.2310, pp.1235-1243, 2012.

D. Hong, R. Gupta, and P. Ancliff, Initiating and Cancer-Propagating Cells in TEL-AML1-Associated Childhood Leukemia, Science, vol.10, issue.16, pp.336-339, 2008.
DOI : 10.1158/1078-0432.CCR-04-0584

T. Burmeister, N. Gokbuget, and S. Schwartz, Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia, Haematologica, vol.95, issue.2, pp.241-246, 2010.
DOI : 10.3324/haematol.2009.011346

K. Paulsson, H. Lilljebjörn, and A. Biloglav, The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia, Nature Genetics, vol.47, issue.6, pp.672-676, 2015.
DOI : 10.1073/pnas.1006981107

N. Dastugue, S. Suciu, and G. Plat, Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results, Blood, vol.121, issue.13, pp.2415-2423, 2013.
DOI : 10.1182/blood-2012-06-437681

V. Mühlbacher, M. Zenger, and S. Schnittger, Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%: Characterization of Low Hypodiploid ALL Molecular cytogenetic characterization ofTCF3 (E2A)/19p13.3 rearrangements in B-cell precursor acute lymphoblastic leukemia, Genes Chromosomes Cancer Genes Chromosomes Cancer, vol.5346, issue.65, pp.524-536, 2007.

M. Kamps, E2A-Pbx1 induces growth, blocks differentiation, and interacts with other homeodomain proteins regulating normal differentiation Hunger SP, Mullighan CG. Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine Activation of the interleukin-3, Curr Top Microbiol Immunol Blood, vol.125, issue.26, pp.22025-22068, 1997.
DOI : 10.1007/978-3-642-60479-9_2

E. Chapiro, I. Radford-weiss, and H. Cung, Chromosomal translocations involving the IGH@ locus in B-cell precursor acute lymphoblastic leukemia: 29 new cases and a review of the literature Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia, gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. Blood FLT3 Mutations in Early T-Cell Precursor ALL Characterize a Stem Cell Like Leukemia and Imply the Clinical Use of Tyrosine Kinase Inhibitorse53190. 36. Wood BL, Winter SS, Dunsmore KP, et al. T-Lymphoblastic Leukemia (T-ALL) Shows Excellent Outcome, Lack of Significance of the Early Thymic Precursor (ETP), pp.162-173147, 2009.

. Immunophenotype, Validation of the Prognostic Value of End-Induction Minimal Residual Disease (MRD) in Children's Oncology Group (COG) Study AALL0434, Blood, vol.124, issue.21, pp.1-1, 2014.

P. Kastner, A. Dupuis, M. Gaub, R. Herbrecht, P. Lutz et al., Function of Ikaros as a tumor suppressor in B cell acute lymphoblastic leukemia, Am J Blood Res, vol.3, issue.1, pp.1-13, 2013.

C. Mullighan, X. Su, and J. Zhang, and Prognosis in Acute Lymphoblastic Leukemia, New England Journal of Medicine, vol.360, issue.5, pp.470-480, 2009.
DOI : 10.1056/NEJMoa0808253

I. Iacobucci, C. Storlazzi, and D. Cilloni, Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP), Blood, vol.114, issue.10, pp.2159-2167, 2009.
DOI : 10.1182/blood-2008-08-173963

R. Kuiper, E. Waanders, and V. Van-der-velden, IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL, Leukemia, vol.24, issue.7, pp.1258-1264, 2010.
DOI : 10.1073/pnas.0903142106

K. Roberts, Y. Li, and D. Payne-turner, Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia, New England Journal of Medicine, vol.371, issue.11, pp.1005-1015, 2014.
DOI : 10.1056/NEJMoa1403088

T. Herold, S. Schneider, and K. Metzeler, Philadelphia chromosome-like acute lymphoblastic leukemia in adults have frequent IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis. Haematologica [Epub ahead of print]. 43. Ofran Y, Izraeli S. BCR-ABL (Ph)-like acute leukemia?Pathogenesis, diagnosis and therapeutic options, Blood Rev, vol.31, issue.2, pp.11-16, 2017.

T. Herold and N. Gökbuget, Philadelphia-Like Acute Lymphoblastic Leukemia in Adults, Current Oncology Reports, vol.6, issue.4
DOI : 10.1038/bcj.2016.28

V. Asnafi, A. Buzyn, L. Noir, and S. , NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study, Blood, vol.113, issue.17, pp.3918-3924, 2009.
DOI : 10.1182/blood-2008-10-184069

A. Trinquand, A. Tanguy-schmidt, B. Abdelali, and R. , ???Based Oncogenetic Risk Classification of Adult T-Cell Acute Lymphoblastic Leukemia: A Group for Research in Adult Acute Lymphoblastic Leukemia Study, Journal of Clinical Oncology, vol.31, issue.34, pp.4333-4342, 2013.
DOI : 10.1200/JCO.2012.48.5292

D. Hoelzer, E. Thiel, and H. Loffler, Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults, Blood, vol.71, issue.1, pp.123-131, 1988.

J. Gaynor, D. Chapman, and C. Little, A Cause-Specific Hazard Rate Analysis of Prognostic Factors Among 199 Adults With Acute Lymphoblastic Leukemia, Journal of Clinical Oncology, vol.6, issue.9
DOI : 10.1200/JCO.1988.6.9.1522

L. Annino, M. Vegna, and A. Camera, Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study, Blood, vol.99, issue.3, pp.863-871, 2002.
DOI : 10.1182/blood.V99.3.863

J. Takeuchi, T. Kyo, and K. Naito, Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study, Leukemia, vol.16, issue.7, pp.1259-1266, 2002.
DOI : 10.1038/sj.leu.2402526

F. Huguet, T. Leguay, and E. Raffoux, Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

J. Ribera, A. Oriol, and C. Bethencourt, Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial, Haematologica, vol.90, issue.10, pp.1346-1356, 2005.

R. Bassan and D. Hoelzer, Modern Therapy of Acute Lymphoblastic Leukemia, Journal of Clinical Oncology, vol.29, issue.5, pp.532-543, 2011.
DOI : 10.1200/JCO.2010.30.1382

L. Drew, Pharmacogenetics: The right drug for you, Nature, vol.537, issue.7619, pp.60-62, 2016.
DOI : 10.1038/537S60a

C. Pui, L. Robison, and A. Look, Acute lymphoblastic leukaemia, The Lancet, vol.371, issue.9617, pp.1030-1043, 2008.
DOI : 10.1016/S0140-6736(08)60457-2

M. Lopez-santillan, L. Iparraguirre, I. Martin-guerrero, A. Gutierrez-camino, A. Garcia-orad et al., Review of pharmacogenetics studies of L-asparaginase hypersensitivity in acute lymphoblastic leukemia points to variants in the GRIA1 gene Pharmacogenomics of pediatric acute lymphoblastic leukemia, Drug Metab Pers Ther Expert Opin Pharmacother, vol.3211, issue.110, pp.1-9, 2010.

M. Stanulla, E. Schaeffeler, and T. Flohr, Thiopurine Methyltransferase (<EMPH TYPE="ITAL">TPMT</EMPH>) Genotype and Early Treatment Response to Mercaptopurine in Childhood Acute Lymphoblastic Leukemia, JAMA, vol.293, issue.12, pp.1485-1489, 2005.
DOI : 10.1001/jama.293.12.1485

J. Simone, M. Verzosa, and J. Rudy, Initial features and prognosis in 363 children with acute lymphocytic leukemia, Cancer, vol.15, issue.6, pp.2099-2108, 1975.
DOI : 10.1002/cncr.2820360926

W. Crist, J. Boyett, J. Pullen, J. Van-eys, and T. Vietti, Clinical and biologic features predict poor prognosis in acute lymphoid leukemias in children and adolescents: A pediatric oncology group review, Medical and Pediatric Oncology, vol.98, issue.3, pp.135-139, 1986.
DOI : 10.1007/978-3-642-82249-0_6

R. Bassan, O. Spinelli, and E. Oldani, Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL), Blood, vol.113, issue.18, pp.4153-4162, 2009.
DOI : 10.1182/blood-2008-11-185132

O. Reman, A. Pigneux, and F. Huguet, Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: Results from the GET-LALA group, Leukemia Research, vol.32, issue.11, pp.1741-1750, 2008.
DOI : 10.1016/j.leukres.2008.04.011

D. Fière, E. Lepage, and C. Seban, Adult Acute Lymphoblastic Leukemia: A Multicentric Randomized Trial Testing Bone Marrow Transplantation as Postremission TherapyEpub ahead of print]. 65. Lazarus HM. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993, J Clin Oncol Blood, vol.108, issue.2, pp.465-472, 2006.

X. Thomas and Q. Le, Central nervous system involvement in adult acute lymphoblastic leukemia, Hematology, vol.17, issue.1, pp.293-302, 2008.
DOI : 10.1200/JCO.1999.17.12.3745

D. Stewart, M. Keating, and K. Mccreddy, Natural History of Central Nervous System Acute Leukemia in Adults. Cancer [Epub ahead of print]. 68 Childhood T-Cell Acute Lymphoblastic Leukemia: The Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Experience, J Clin Oncol, vol.21, pp.3616-3622, 2003.

D. Thomas, O. Brien, S. Jorgensen, and J. , Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia, Blood, vol.113, issue.25, pp.6330-6337, 2009.
DOI : 10.1182/blood-2008-04-151860

S. Maury, S. Chevret, and X. Thomas, Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia, New England Journal of Medicine, vol.375, issue.11, pp.1044-1053, 2016.
DOI : 10.1056/NEJMoa1605085

B. Gleissner, CD10- pre-B acute lymphoblastic leukemia (ALL) is a distinct high-risk subgroup of adult ALL associated with a high frequency of MLL aberrations: results of the German Multicenter Trials for Adult ALL (GMALL), Blood, vol.106, issue.13, pp.4054-4056, 2005.
DOI : 10.1182/blood-2005-05-1866

H. Riehm, A. Reiter, and M. Schrappe, Die Corticosteroid-abh??ngige Dezimierung der Leuk??miezellzahl im Blut als Prognosefaktor bei der akuten lymphoblastischen Leuk??mie im Kindesalter (Therapiestudie ALL-BFM 83), Klinische P??diatrie, vol.199, issue.03, pp.151-160, 1987.
DOI : 10.1055/s-2008-1026781

X. Thomas, J. Boiron, and F. Huguet, Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial, Journal of Clinical Oncology, vol.22, issue.20, pp.4075-4086, 2004.
DOI : 10.1200/JCO.2004.10.050

M. Schrappe, Detection and management of minimal residual disease in acute lymphoblastic leukemia, Hematology, vol.2014, issue.1, pp.244-249, 2014.
DOI : 10.1182/asheducation-2014.1.244

H. Cavé, . Van-der-werff-ten, J. Bosch, and S. Suciu, Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia, New England Journal of Medicine, vol.339, issue.9, pp.591-598, 1998.
DOI : 10.1056/NEJM199808273390904

V. Conter, C. Bartram, and M. Valsecchi, Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study, Blood, vol.115, issue.16, pp.3206-3214, 2010.
DOI : 10.1182/blood-2009-10-248146

T. Raff, N. Gökbuget, and S. Lüschen, Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials, Blood, vol.109, issue.3, pp.910-915, 2007.
DOI : 10.1182/blood-2006-07-037093

M. Brüggemann, T. Raff, and T. Flohr, Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia, Blood, vol.107, issue.3, pp.1116-1123, 2006.
DOI : 10.1182/blood-2005-07-2708

K. Beldjord, S. Chevret, and V. Asnafi, Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It Healthcare burden and reimbursement of hospitalization during chemotherapy for adults with Ph-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in France: a retrospective chart review, Blood Curr Oncol Rep J Med Econ, vol.1231919, issue.24111, pp.3739-3749, 2014.

H. Kantarjian, O. Brien, and S. , Insurance policies in the United States may explain part of the outcome differences of adolescents and young adults with acute lymphoblastic leukemia treated on adult versus pediatric regimens, Blood, vol.113, issue.8, pp.1861-1861, 2009.
DOI : 10.1182/blood-2008-10-186718

E. Petridou, T. Sergentanis, and C. Perlepe, Socioeconomic disparities in survival from childhood leukemia in the United States and globally: a meta-analysis, Annals of Oncology, vol.26, issue.3, pp.589-597, 2015.
DOI : 10.1093/annonc/mdu572

S. Giebel, M. Labopin, and A. Ibatici, Association of Macroeconomic Factors With Nonrelapse Mortality After Allogeneic Hematopoietic Cell Transplantation for Adults With Acute Lymphoblastic Leukemia: An Analysis From the Acute Leukemia Working Party of the EBMT, The Oncologist, vol.21, issue.3, pp.377-3833463, 2014.
DOI : 10.1634/theoncologist.2015-0314

E. Freireich, A. Tanguy-schmidt, P. Rousselot, and Y. Chalandon, The History of Leukemia Therapy?A Personal Journey Long-Term Follow-Up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A GRAALL Study, Clin Lymphoma Myeloma Leuk Biol Blood Marrow Transplant, vol.1219, issue.881, pp.386-392150, 2012.

D. Hoelzer, R. Bassan, H. Dombret, A. Fielding, J. Ribera et al., Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.025, 2016.
DOI : 10.1093/annonc/mdw025

C. Hyman and P. Sturgeon, Prednison therapy of acute lymphatic leukemia in children, Cancer, vol.41, issue.5, pp.965-970, 1956.
DOI : 10.7326/0003-4819-41-3-447

O. Teuffel, S. Kuster, and S. Hunger, Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis, Leukemia, vol.5, issue.8, pp.1232-1238, 2011.
DOI : 10.1002/(SICI)1096-911X(199608)27:2<114::AID-MPO8>3.0.CO;2-I

C. Dumontet and B. Sikic, Mechanisms of Action of and Resistance to Antitubulin Agents: Microtubule Dynamics, Drug Transport, and Cell Death, Childhood Acute Lymphoblastic Leukaemia Collaborative Group (CALLCG), pp.1061-1070, 1999.
DOI : 10.1200/JCO.1999.17.3.1061

A. Gottlieb, V. Weinberg, and R. Ellison, Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by cancer and leukemia group B, Blood, vol.64, issue.1, pp.267-274, 1984.

J. Jolivet, K. Cowan, G. Curt, N. Clendeninn, and B. Chabner, The Pharmacology and Clinical Use of Methotrexate, New England Journal of Medicine, vol.309, issue.18, pp.1094-1104, 1983.
DOI : 10.1056/NEJM198311033091805

S. Reutenauer, D. Chauveau, and C. Récher, Surdosage au m??thotrexate??: complications, prise en charge et pr??vention, R??animation, vol.18, issue.7, pp.654-658, 2009.
DOI : 10.1016/j.reaurg.2009.06.018

I. Djerassi, Methotrexate infusions and intensive supportive care in the management of children with acute lymphocytic leukemia: follow-up report, Cancer Res, vol.27, issue.12, pp.2561-2564, 1967.

N. Gökbuget and D. Hoelzer, High-dose methotrexate in the treatment of adult acute lymphoblastic leukemia, Annals of Hematology, vol.72, issue.4, pp.194-201, 1996.
DOI : 10.1007/s002770050160

J. Koprivnikar, J. Mccloskey, and S. Faderl, Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia, OncoTargets and Therapy, vol.10, pp.101413-1422, 2017.
DOI : 10.2147/OTT.S106810

M. Sweeney, A. Tuttle, J. Etteldorf, and G. Whittington, Cyclophosphamide in the treatment of common neoplastic diseases of childhood, The Journal of Pediatrics, vol.61, issue.5, pp.61702-708, 1962.
DOI : 10.1016/S0022-3476(62)80341-2

M. Relling, M. Hancock, J. Boyett, C. Pui, and W. Evans, Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia, Blood, vol.93, issue.9, pp.2817-2823, 1999.

B. Oliveira, . De, M. Valadares, M. Silva, and M. Viana, Compliance with a protocol for acute lymphoblastic leukemia in childhood, Revista Brasileira de Hematologia e Hemoterapia, vol.33, issue.3, pp.185-189, 2011.
DOI : 10.5581/1516-8484.20110051

A. Yeoh, A. Collins, and K. Fox, Treatment delay and the risk of relapse in pediatric acute lymphoblastic leukemia, Pediatric Hematology and Oncology, vol.11, issue.1, pp.38-42, 2017.
DOI : 10.1097/MPH.0000000000000206

M. Schrappe, A. Möricke, and A. Reiter, Key Treatment Questions in Childhood Acute Lymphoblastic Leukemia: Results in 5 Consecutive Trials Performed by the ALL-BFM Study Group From, Klin Pädiatr, vol.225, pp.62-72, 1981.

M. Dördelmann, A. Reiter, and A. Borkhardt, Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia, Blood, vol.94, issue.4, pp.1209-1217, 1999.

H. Riehm, H. Gadner, and K. Welte, Die West-Berliner Studie zur Behandlung der akuten lymphoblastischen Leukämie des Kindes-Erfahrungsbericht nach 6 Jahren, Klin Pädiatr, vol.225, pp.16-29, 2013.

A. Möricke, M. Zimmermann, and A. Reiter, Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000, Leukemia, vol.21, issue.2, pp.265-284, 1981.
DOI : 10.1038/leu.2009.17

H. Langermann, G. Henze, M. Wulf, and H. Riehm, Absch??tzung der Tumorzellmasse bei der akuten lymphoblastischen Leuk??mie im Kindesalter: prognostische Bedeutung und praktische Anwendung*, Klinische P??diatrie, vol.194, issue.04, pp.209-213, 1982.
DOI : 10.1055/s-2008-1033807

A. Moricke, A. Reiter, and M. Zimmermann, Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95, Blood, vol.111, issue.9, pp.4477-4489, 2008.
DOI : 10.1182/blood-2007-09-112920

G. Henze, H. Langermann, and J. Brämswig, Ergebnisse der Studie BFM 76/79 zur Behandlung der akuten lymphoblastischen Leuk??mie bei Kindern und Jugendlichen*, Ergebnisse der Studie BFM 76/79 zur Behandlung der akuten lymphoblastischen Leukämie bei Kindern und Jugendlichen, pp.145-154, 1981.
DOI : 10.1055/s-2008-1034450

D. Tubergen, G. Gilchrist, O. Brien, and R. , Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial., Journal of Clinical Oncology, vol.11, issue.3, pp.527-537, 1993.
DOI : 10.1200/JCO.1993.11.3.527

S. Bhatia, W. Landier, and L. Hageman, 6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study, Blood, vol.124, issue.15, pp.2345-2353, 2014.
DOI : 10.1182/blood-2014-01-552166

H. Dombret, T. Cluzeau, F. Huguet, and N. Boissel, Pediatric-Like Therapy for Adults with ALL, Current Hematologic Malignancy Reports, vol.118, issue.11, pp.158-164, 2014.
DOI : 10.1182/blood-2011-05-351403

H. Kantarjian, O. Brien, S. Smith, and T. , Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia, Journal of Clinical Oncology, vol.18, issue.3, pp.547-561, 2000.
DOI : 10.1200/JCO.2000.18.3.547

S. Murphy, W. Bowman, and M. Abromowitch, Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine., Journal of Clinical Oncology, vol.4, issue.12, pp.1732-1739, 1986.
DOI : 10.1200/JCO.1986.4.12.1732

S. Faderl, D. Thomas, O. Brien, and S. , Augmented Hyper-CVAD Based on Dose-Intensified Vincristine, Dexamethasone, and Asparaginase in Adult Acute Lymphoblastic Leukemia Salvage Therapy, Clinical Lymphoma Myeloma and Leukemia, vol.11, issue.1, pp.54-59, 2011.
DOI : 10.3816/CLML.2011.n.007

N. Boissel, M. Auclerc, and V. Lhéritier, Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials, Journal of Clinical Oncology, vol.21, issue.5, pp.774-780, 2003.
DOI : 10.1200/JCO.2003.02.053

J. De-bont, B. Holt, . Van-der, A. Dekker, . Van-der-does-van-den et al., Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands, Leukemia, vol.18, issue.12, pp.2032-2035, 2004.
DOI : 10.1038/sj.leu.2403538

R. Ramanujachar, S. Richards, and I. Hann, Adolescents with acute lymphoblastic leukaemia: Outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials, Pediatric Blood & Cancer, vol.44, issue.3, pp.254-261, 2007.
DOI : 10.1002/pbc.20749

H. Hallböök, G. Gustafsson, B. Smedmyr, S. Söderhäll, and M. Heyman, Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden, Cancer, vol.16, issue.7, pp.1551-1561, 2006.
DOI : 10.1002/cncr.22189

W. Stock, L. M. Sanford, and B. , What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies, Blood, vol.112, issue.5, pp.1646-1654, 2008.
DOI : 10.1182/blood-2008-01-130237

D. Deangelo, S. Dahlberg, and L. Silverman, A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia, Blood, vol.110, issue.11, pp.587-587, 2007.

D. Douer, K. Watkins, and L. Mark, A Dose Intensified Pediatric-Like Regimen Using Multiple Doses of Intravenous Pegylated Asparaginase in Adults with Newly Diagnosed Acute Lymphoblastic Leukemia, Blood, vol.110, issue.11, pp.2823-2823, 2007.

S. Haïat, Z. Marjanovic, and S. Lapusan, Outcome of 40 adults aged from 18 to 55 years with acute lymphoblastic leukemia treated with double-delayed intensification pediatric protocol, Leukemia Research, vol.35, issue.1, pp.66-72, 2011.
DOI : 10.1016/j.leukres.2010.04.002

J. Ribera, A. Oriol, and M. Sanz, Comparison of the Results of the Treatment of Adolescents and Young Adults With Standard-Risk Acute Lymphoblastic Leukemia With the Programa Espa??ol de Tratamiento en Hematolog??a Pediatric-Based Protocol ALL-96, Journal of Clinical Oncology, vol.26, issue.11, pp.1843-1849, 2008.
DOI : 10.1200/JCO.2007.13.7265

S. Daenen, B. Van-der-holt, and A. Dekker, Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40: a phase II study for efficacy and feasibility by HOVON, Leukemia, vol.78, issue.7, pp.1726-1729, 2012.
DOI : 10.1007/s12185-008-0223-z

T. Cluzeau, N. Dhedin, and F. Huguet, Dose-Intensity Impacts On Survival of Adolescents and Young Adults with Acute Lymphoblastic Leukemia Treated in Adult Departments by a Pediatric Protocol, Blood, vol.120, issue.21, pp.3561-3561, 2000.

T. Sakura, F. Hayakawa, and T. Yujiri, Outcome of Pediatric-Type Therapy for Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults (AYA): A Study by the Japan Adult Leukemia Study Group (JALSG ALL202-U study), Blood, vol.120, issue.21, pp.1464-1464, 2012.

M. Rytting, E. Jabbour, and J. Jorgensen, Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-M??nster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen, American Journal of Hematology, vol.385, issue.8, pp.819-823, 2016.
DOI : 10.1016/S1474-4422(13)70240-0

M. Rytting, D. Thomas, O. Brien, and S. , Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL)

J. Hocking, A. Schwarer, and R. Gasiorowski, Excellent outcomes for adolescents and adults with acute lymphoblastic leukemia and lymphoma without allogeneic stem cell transplant: the FRALLE-93 pediatric protocol, Leukemia & Lymphoma, vol.95, issue.12, pp.2801-2807, 2014.
DOI : 10.1200/JCO.2008.18.6916

I. Alacacioglu, S. Medeni, and G. Ozsan, Is the BFM Regimen Feasible for the Treatment of Adult Acute Lymphoblastic Leukemia? A Retrospective Analysis of the Outcomes of BFM and Hyper-CVAD Chemotherapy in Two Centers, Chemotherapy, vol.60, issue.4, pp.219-223, 2015.
DOI : 10.1159/000375258

B. Sanford, S. Luger, and M. Devidas, Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance), Blood, vol.122, issue.21, pp.3903-3903, 2013.

J. El-cheikh, E. Dika, I. Massoud, and R. , Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis, Clinical Lymphoma Myeloma and Leukemia, vol.17, issue.3, pp.179-185, 2017.
DOI : 10.1016/j.clml.2016.11.002

H. Kantarjian, A. Stein, and N. Gökbuget, Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia, New England Journal of Medicine, vol.376, issue.9, pp.836-847, 2017.
DOI : 10.1056/NEJMoa1609783

M. Topp, N. Gökbuget, and G. Zugmaier, Phase II Trial of the Anti-CD19 Bispecific T Cell???Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia, Journal of Clinical Oncology, vol.32, issue.36, pp.4134-4140, 2014.
DOI : 10.1200/JCO.2014.56.3247

X. Thomas, L. Jeune, and C. , Treating adults with acute lymphocytic leukemia: new pharmacotherapy options, Expert Opinion on Pharmacotherapy, vol.126, issue.23, pp.2319-2330, 2016.
DOI : 10.1111/ejh.12234

H. Kantarjian, D. Deangelo, and M. Stelljes, Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia, New England Journal of Medicine, vol.375, issue.8, pp.740-753, 2016.
DOI : 10.1056/NEJMoa1509277

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5594743/pdf

E. Jabbour, O. Brien, S. Sasaki, and K. , Frontline Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Acute Lymphoblastic Leukemia (ALL), Blood, vol.126, issue.23, pp.83-83, 2015.

N. Gokbuget, N. Basara, and H. Baurmann, High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation, Blood, vol.118, issue.13, pp.3504-3511, 2011.
DOI : 10.1182/blood-2011-01-329441

D. Marks and C. Rowntree, Management of adults with T-cell lymphoblastic leukemia, Blood, vol.129, issue.9, pp.1134-1142, 2017.
DOI : 10.1182/blood-2016-07-692608

N. Dhédin, A. Huynh, and S. Maury, Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia, Blood, vol.125, issue.16, pp.2486-2496, 2015.
DOI : 10.1182/blood-2014-09-599894

R. Dhawan and D. Marks, Who Should Receive a Transplant for Acute Lymphoblastic Leukaemia?, Current Hematologic Malignancy Reports, vol.371, issue.16
DOI : 10.1056/NEJMoa1407222

M. Seftel, D. Neuberg, and M. Zhang, Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission, American Journal of Hematology, vol.38, issue.3, pp.322-329, 2016.
DOI : 10.1016/j.leukres.2013.10.021

N. Gokbuget, How I treat older patients with ALL, Blood, vol.122, issue.8, pp.1366-1375, 2013.
DOI : 10.1182/blood-2012-07-379016

A. Moorman, L. Chilton, J. Wilkinson, H. Ensor, N. Bown et al., A population-based cytogenetic study of adults with acute lymphoblastic leukemia, Blood, vol.115, issue.2, pp.206-214, 2010.
DOI : 10.1182/blood-2009-07-232124

C. Saillard, E. A. Charbonnier, and A. , Evaluation of comorbidity indexes in the outcome of elderly patients treated for acute lymphoblastic leukemia, Leukemia & Lymphoma, vol.55, issue.9, pp.2211-2212, 2014.
DOI : 10.1182/blood-2012-12-471680

L. Noens, Geriatrics and haematological malignancies: is comprehensive geriatric assessment a useful tool?, European Journal of Cancer, vol.47, pp.47-362, 2011.
DOI : 10.1016/S0959-8049(11)70204-0

P. Caillet, F. Canoui-poitrine, and J. Vouriot, Comprehensive Geriatric Assessment in the Decision-Making Process in Elderly Patients With Cancer: ELCAPA Study, Journal of Clinical Oncology, vol.29, issue.27, pp.3636-3642, 2011.
DOI : 10.1200/JCO.2010.31.0664

M. Hamaker, M. Prins, and R. Stauder, The relevance of a geriatric assessment for elderly patients with a haematological malignancy ??? A systematic review, Leukemia Research, vol.38, issue.3, pp.275-283, 2014.
DOI : 10.1016/j.leukres.2013.12.018

H. Klepin, A. Geiger, and J. Tooze, Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia, Blood, vol.121, issue.21, pp.4287-4294, 2013.
DOI : 10.1182/blood-2012-12-471680

P. Soubeyran, C. Bellera, and J. Goyard, Screening for Vulnerability in Older Cancer Patients: The ONCODAGE Prospective Multicenter Cohort Study, PLoS ONE, vol.49, issue.12, p.115060, 2014.
DOI : 10.1371/journal.pone.0115060.s002

A. Velghe, M. Petrovic, D. Buyser, S. Demuynck, R. Noens et al., Validation of the G8 screening tool in older patients with aggressive haematological malignancies, European Journal of Oncology Nursing, vol.18, issue.6, pp.645-648, 2014.
DOI : 10.1016/j.ejon.2014.05.006

M. Hamaker, M. Mitrovic, and R. Stauder, The G8 screening tool detects relevant geriatric impairments and predicts survival in elderly patients with a haematological malignancy, Annals of Hematology, vol.53, issue.10, pp.1031-1040, 2014.
DOI : 10.1111/j.1532-5415.2005.53501.x

C. Townsley, R. Selby, and L. Siu, Systematic Review of Barriers to the Recruitment of Older Patients With Cancer Onto Clinical Trials, Journal of Clinical Oncology, vol.23, issue.13, pp.3112-3124, 2005.
DOI : 10.1200/JCO.2005.00.141

A. Hurria, S. Mohile, and W. Dale, Research Priorities in Geriatric Oncology: Addressing the Needs of an Aging Population, Journal of the National Comprehensive Cancer Network, vol.10, issue.2, pp.286-288, 2012.
DOI : 10.6004/jnccn.2012.0025

L. Hutchins, J. Unger, J. Crowley, C. Jr, C. Albain et al., Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials, New England Journal of Medicine, vol.341, issue.27, pp.2061-2067, 1999.
DOI : 10.1056/NEJM199912303412706

M. Hamaker, R. Stauder, and B. Van-munster, Exclusion of Older Patients From Ongoing Clinical Trials for Hematological Malignancies: An Evaluation of the National Institutes of Health Clinical Trial Registry, The Oncologist, vol.19, issue.10, pp.1069-1075, 2014.
DOI : 10.1634/theoncologist.2014-0093

J. Sive, G. Buck, and A. Fielding, Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial, British Journal of Haematology, vol.93, issue.4, pp.463-471, 2012.
DOI : 10.1200/JCO.2010.32.7270

L. Annino, N. Goekbuget, and A. Delannoy, Acute lymphoblastic leukemia in the elderly, The Hematology Journal, vol.3, issue.5
DOI : 10.1038/sj.thj.6200189

A. Delannoy, A. Ferrant, and A. Bosly, Acute lymphoblastic leukemia in the elderly, European Journal of Haematology, vol.64, issue.2, pp.90-93, 1990.
DOI : 10.1056/NEJM198509053131016

URL : https://hal.archives-ouvertes.fr/hal-00821138

H. Kantarjian, O. Brien, S. Smith, and T. , Acute lymphocytic leukaemia in the elderly: characteristics and outsome with the vincristine-adriamycin-dexamethasone (VAD) regimen, British Journal of Haematology, vol.80, issue.1
DOI : 10.2307/2281868

E. Nagura, S. Minami, and K. Nagata, Analysis of Elderly Patients, Aged 60 Years Old or over, with Acute Lymphoblastic Leukemia., Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics, vol.36, issue.1, pp.52-58, 1999.
DOI : 10.3143/geriatrics.36.52

T. Robak, Acute Lymphoblastic Leukaemia in Elderly Patients, Drugs & Aging, vol.18, issue.12, pp.779-791, 2004.
DOI : 10.2165/00002512-200421120-00003

E. Späth-schwalbe, G. Heil, and H. Heimpel, Acute lymphoblastic leukemia in patients over 59 years of age, Annals of Hematology, vol.56, issue.S2, pp.291-296, 1994.
DOI : 10.1038/bjc.1986.32

X. Thomas, N. Olteanu, C. Charrin, V. Lhéritier, J. Magaud et al., Acute lymphoblastic leukemia in the elderly: The Edouard Herriot hospital experience, American Journal of Hematology, vol.9, issue.Suppl 1, pp.73-83, 2001.
DOI : 10.1200/JCO.1991.9.5.777

F. Huguet and T. Leguay, The Upper Age Limit for a Pediatric-Inspired Therapy in Younger Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL)? Analysis of the Graall, 2005.

R. Bassan, E. Bona, and T. Lerede, Age-Adapted Moderate-Dose Induction and Flexible Outpatient Postremission Therapy for Elderly Patients with Acute Lymphoblastic Leukemia, Leukemia & Lymphoma, vol.83, issue.1, pp.3-4295, 1996.
DOI : 10.1111/j.1365-2141.1995.tb03312.x

M. Offidani, L. Corvatta, and L. Malerba, Comparison of two regimens for the treatment of elderly patients with acute lymphoblastic leukaemia (ALL), Leukemia & Lymphoma, vol.88, issue.2, pp.233-238, 2005.
DOI : 10.1182/blood-2003-08-2958

M. Hunault-berger, T. Leguay, and X. Thomas, A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study, Haematologica, vol.96, issue.2, pp.245-252, 2011.
DOI : 10.3324/haematol.2010.027862

URL : https://hal.archives-ouvertes.fr/hal-00821138

J. Sancho, J. Ribera, and B. Xicoy, Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia, European Journal of Haematology, vol.104, issue.1, p.061114074547002, 2006.
DOI : 10.1182/blood-2004-11-4541

S. Kao, W. Xu, and V. Gupta, Outcome of Patients Age 60 and Over with Acute Lymphoblastic Leukemia (ALL) Treated with a Modified Pediatric Protocol [Abstract], Blood, vol.112, issue.11, pp.3962-3962, 2008.

A. Fathi, D. Deangelo, and K. Stevenson, Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia, Cancer, vol.126, issue.15, pp.2379-2388, 2016.
DOI : 10.1016/S1470-2045(14)71170-2

M. Hunault-berger, T. Leguay, and F. Huguet, A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study, American Journal of Hematology, vol.26, issue.9, pp.811-818, 2015.
DOI : 10.1038/leu.2012.53

URL : https://hal.archives-ouvertes.fr/hal-01237093

N. Goekbuget, T. Leguay, and M. Hunault, First European Chemotherapy Schedule for Elderly Patients with Acute Lymphoblastic Leukemia: Promising Remission Rate and Feasible Moderate Dose Intensity Consolidation, Blood, vol.112, issue.11, pp.304-304, 2008.

P. Schwartz, M. Hunaut-berger, and P. Chevallier, French results with the EWALL chemotherapy backbone in older patients with philadelphia chromosome-negative acute lymphoblastic leukemia

J. Ribera, O. García, and A. Oriol, Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group, Leukemia Research, vol.41, pp.4112-4132, 2016.
DOI : 10.1016/j.leukres.2015.11.012

N. Goekbuget, J. Beck, and M. Brueggemann, Moderate Intensive Chemotherapy Including CNS-Prophylaxis with Liposomal Cytarabine Is Feasible and effective in Older Patients with Ph-Negative Acute Lymphoblastic Leukemia (ALL): Results of a Prospective Trial From the German Multicenter Study Group for Adult ALL (GMALL), Blood, vol.120, issue.21, pp.1493-1493, 2012.

O. 'brien, S. Thomas, D. Ravandi, F. Faderl, S. Pierce et al., Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia, Cancer, vol.109, issue.8, pp.2097-2101, 2008.
DOI : 10.1002/cncr.23819

P. Martell, M. Atenafu, E. Minden, and M. , Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol, British Journal of Haematology, vol.109, issue.4, pp.458-464, 2013.
DOI : 10.1182/blood-2006-10-052746

H. Kantarjian, A. Stein, and R. Bargou, Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies, Cancer, vol.33, issue.suppl 4, pp.2178-2185, 2016.
DOI : 10.1200/JCO.2014.60.1203

K. Sasaki, E. Jabbour, O. Brien, and S. , Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial, Blood, vol.128, issue.22, pp.588-588, 2016.

R. Martino, S. Giralt, and M. Caballero, Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study, Haematologica, vol.88, issue.5, pp.555-560, 2003.

T. Hamaki, M. Kami, and Y. Kanda, Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: a retrospective study of 33 patients, Bone Marrow Transplantation, vol.35, issue.6, pp.549-556, 2005.
DOI : 10.1038/sj.bmt.1704776

M. Mohty, M. Labopin, and L. Volin, Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation, Blood, vol.116, issue.22, pp.4439-4443, 2010.
DOI : 10.1182/blood-2010-02-266551

D. Marks, L. Alonso, and R. Radia, Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia, Hematology/Oncology Clinics of North America, vol.28, issue.6, pp.995-1009, 2014.
DOI : 10.1016/j.hoc.2014.08.008

O. Wolach, K. Stevenson, and M. Wadleigh, Allogeneic transplantation is not superior to chemotherapy in most patients over 40??years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission, American Journal of Hematology, vol.21, issue.19, pp.793-799, 2016.
DOI : 10.1158/1078-0432.CCR-15-0125

M. Hunault-berger, P. Chevallier, and M. Delain, Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study, Haematologica, vol.93, issue.10, pp.1488-1494, 2008.
DOI : 10.3324/haematol.12948

W. Stock, D. Douer, and D. Deangelo, Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel, Leukemia & Lymphoma, vol.112, issue.1, pp.2237-2253, 2011.
DOI : 10.1007/978-1-4615-6628-1_16

N. Gokbuget, First analysis of prognostic factors in elderly Ph/BCR-ABL negative ALL including comorbidity scores: Different factors predict mortality and relapse, Onkologie, vol.31, issue.4, pp.1-240, 2008.